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Abstract
In situ tissue regeneration approach aims to exploit the body’s own biological resources and reparative capability
and recruit host cells by utilizing cell-instructive biomaterials. In order to immobilize and release bioactive factors
in biomaterials, it is important to engineer the load effectiveness, release kinetics and cell recruiting capabilities of
bioactive molecules by using suitable bonding strategies. Stromal cell-derived factor 1α (SDF-1α) is one of the most
potent chemokines for stem cell recruitment, and SDF-1α-loaded scaffolds have been used for the regeneration of
many types of tissues. This review summarizes the strategies to incorporate SDF-1α into scaffolds, including direct
loading or adsorption, polyion complexes, specific heparin-mediated interaction and particulate system, which may
be applied to the immobilization of other chemokines or growth factors. In addition, we discuss the application of
these strategies in the regeneration of tissues such as blood vessel, myocardium, cartilage and bone.
Keywords: In-situ tissue engineering, Stromal cell-derived factor, Cell-instructive biomaterials, Bonding interaction,
Chemokine
Background
Tissue engineering combines the knowledge and tech-
nologies in engineering, biology and medicine to promote
the regeneration of tissues and the restoration of tissue
and organ function. In the past two decades, the ap-
proaches of tissue engineering have evolved to facilitate
the translation of research findings and technologies into
clinical applications [1–3]. A classical approach of tissue
engineering is to fabricate bioengineered tissues or organs
by culturing allogeneic or autologous cells on the scaffold
in vitro, followed by the implantation of the cellular con-
structs. However, this strategy presents several notable
disadvantages: cell culture is costly and time-consuming;
there may be a phenotypic change of the cells during cell
expansion, cellular construct has limited shelf life and is
vulnerable to contamination; and only a fraction of seed
cells actually contribute to tissue formation. Recent pro-
gress in tissue engineering and regenerative medicine has
resulted in the adoption of the concept of the utilization
of cell-instructive biomaterials with bioactive molecules
for in situ tissue engineering [4, 5].
Rather than implanting cells or tissue grown in vitro,
in situ tissue engineering involves the implantation of
bioactive scaffold material decorated with, or eluting,
bioactive factors into the tissue defect in order to engage
the natural regeneration capacity of the host by recruit-
ing stem cells or progenitor cells. In some types of tis-
sues, the number of adult stem cells surrounding an
implanted scaffold may be too low to have a significant
impact on the acceleration of tissue regeneration [4].
Recent studies have proven that stem cells from the
blood circulation can play a significant role in
vascularization, hematopoiesis and mesenchymal tissue
regeneration [6, 7]. Therefore, it is also valuable to
mobilize progenitors from the peripheral blood system.
Stromal cell-derived factor-1α (SDF-1α) is a member
of the CXC chemokine family of pro-inflammatory
mediators and a potent chemoattractant for a variety of
cells, especially CXC chemokine receptor type 4
(CXCR4) positive progenitors [8, 9]. Upon injury, cells
from the injured tissue express and release a high level
of SDF-1α, which causes a concentration gradient of
SDF-1α from injured tissue to the surrounding micro-
environment. CD34+ progenitor cells from the periph-
eral blood circulation can be recruited via chemotactic
attraction toward this gradient [10, 11]. Some
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investigators have also reported on the role of SDF-
1α in the mobilization and recruitment of bone
marrow-derived hematopoietic stem cells (HSCs) and
mesenchymal stem cells (MSCs), which contribute to
the regeneration of blood vessels, bone, cartilage,
skeletal muscle [12–15]. Some researchers have noted
that the existence of SDF-1α around an in-situ tissue
regeneration scaffold induces cell migration to the
scaffold [15, 16]. Therefore, incorporation of SDF-1α
into a suitable tissue engineering scaffold is an effect-
ive method of recruiting host circulating stem cells to
the target tissue.
Both loading capacity and the release property of SDF-
1α are critical for tissue regeneration. All of the con-
trolled release characteristics are dependent on how
SDF-1α is incorporated into the scaffolds. Hence, this
review summarizes various bonding strategies of SDF-1α
in biomaterials. Additionally, the typical applications of
SDF-1α-loaded scaffolds in the regeneration of blood
vessels, myocardium, cartilage and bone are discussed.
Bonding strategies
In order to achieve in situ tissue regeneration, the re-
lease kinetics, loading efficiency and quantity of SDF-1α-
loaded scaffolds can be engineered through different
bonding strategies. Generally speaking, bonding be-
tween scaffolds and SDF-1α can be classified as phys-
ical and chemical immobilization. Importantly, the
premature degradation of SDF-1α should also be pre-
vented [17, 18]. Table 1 provides a summary of SDF-
1α bonding strategies that have been developed.
Compared with chemical bonding, physical adsorption
is weaker, and has a burst release and short release dur-
ation. Ji et al. suggests that this initial burst release of
SDF-1α is responsible for a more effective recruitment
of stem/progenitor cells and so conducive of superior
clinical outcome [19]. However, Chen et al. holds the op-
posite point of view [20]. They emphasize that the rapid
elution of SDF-1α may lead to some adverse effects. For
example, SDF-1α can be cleaved by various enzymes in-
cluding dipeptidylpeptidase-4 (DPP-4), metalloproteinases
(MMPs) , neutrophil elastase and cathepsin G, leading to
the generation of neurotoxic products which known to be
involved in some forms of dementia [21–25].
Chemical immobilization of bioactive factors onto the
surface of scaffolds is generally superior to physical
immobilization in tissue engineering applications to pre-
vent them being washed out when the scaffold is in con-
tact with fluid over an extended period. Furthermore,
the loading efficiency of chemically immobilized bio-
active factors is generally higher, which avoids wasting
bioactive factors during fabrication. However, denatur-
ation and the loss of bioactivity might happen during
chemical immobilization due to exposure of the loaded
bioactive factors to organic-aqueous interfaces [26, 27].
In addition, the loading procedure is more complicated
than for physical adsorption.
As the synergistic effects between SDF-1α and mul-
tiple chemokines have been observed [28], selecting ap-
propriate bonding strategy for each of the bioactive
factors is also challenging.
Here we review typical bonding strategies SDF-1α
immobilization. We also introduce some technologies
that can be used for the loading of SDF-1α.
Direct loading or adsorption
Direct loading or adsorption of bioactive factors onto
biomaterials is widely used. In this case, chemokines
such as SDF-1α are incorporated during the fabrication
process of the scaffolds, especially hydrogels, because
the reaction process is relatively mild allowing chemo-
kine bioactivity to be retained [29–32]. Alternatively,
physical adsorption can be done by immersing porous
scaffolds in a solution of SDF-1α or injecting SDF-1α
into the scaffold [33–35]. The incorporated SDF-1α can
be released upon the desorption from the scaffold or the
degradation of the scaffold. The release kinetics of this
type of scaffold shows a burst release during the first few
hours and subsequently stable release over the following
few days [19]. However, the loading efficiency of this
kind of scaffold is usually poor.
Some researchers have attempted to improve the ad-
sorption efficiency of protein-loaded scaffolds by some
specific methods that could be employed to load SDF-1α
into a scaffold. For instance, Koh and his colleagues [36]
used inductively-coupled radio-frequency glow discharge
plasma, normally used to clean biomaterials, to improve
the poor loading efficiency of the physical adsorption
process. The plasma could trigger a reaction with poly-
mer scaffolds and break the chemical bonds on the sur-
face. Thus, the surface reactivity of scaffolds was
increased, making it easy for bioactive factors to be
absorbed upon the immersion of the scaffolds in a solu-
tion of chemokine.
Direct loading or adsorption processes are relatively
simple and time-saving. However, the burst release kin-
etics, short release duration and poor loading efficiency
limit its application.
Immobilization through the formation of polyion
complexes
Polyion complexes are formed by electrostatic interac-
tions between charged polyelectrolytes and their oppos-
itely charged partners [37, 38]. The interactions are
relative stable because it would be statistically impossible
for all the ionic interactions on the molecules to dissoci-
ate concurrently [39]. This approach does not require
additional modification of delivery matrices or linker
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molecules for covalent crosslinking before the incorpor-
ation of bioactive factors. Generally speaking, polyion
complexes can be used for the controlled release of mul-
tiple charged therapeutic agents such as polysaccharides,
proteins, polynucleotides and oligo through their coup-
ling to fibers [40, 41] or microcapsules [42–46]. A typ-
ical positively-charged polymer material is chitosan,
while commonly used negatively-charged polymer mate-
rials include sodium carboxymethyl cellulose, sodium
alginate, hyaluronic acid and polyacrylates.
Liao et al. [40] introduced the interfacial polyelectro-
lyte complexation technology to produce drug-loaded
chitosan–alginate fibers. Bioactive agents are dispersed
into either the alginate or chitosan solution prior to fiber
formation. By varying the ratio of the components in the
anionic or cationic polyelectrolyte solution, the release
behavior of the protein or growth factor can be sig-
nificantly altered. In some studies, scaffold materials
were chosen with an isoelectric point (IEP) that
achieved a better coating rate and loading capacity of
SDF-1α [35, 47–49]. When the pH of the medium is
greater than the IEP of the scaffold component, the
material easily absorbs cations, and conversely, when
the pH of the medium is less than the IEP, the
Table 1 Bonding strategies of SDF-1α-loaded scaffolds
Bonding strategy Features Applications (SM; LC; LE) References
Direct loading or
adsorption
Ease of operation; burst release;
short release duration; poor
loading efficiency
hydroxyethyl methacrylate
(HEMA) /hyaluronic acid
(HA) hydrogels;
SDF-1α: 4 μg/ml
[31]
PCL and type B-gelatin;
SDF-1α:2.5 ~ 10 μg/ml
[19]
Immobilization through
the formation of ionic
complexes
Extensive applicability; efficient
dsorption; free of linker molecules;
less dependent on surface
properties; adjustable release rate;
requires cytotoxic surfactants
PGS (PEDA/heparin
coacervate);
SDF-1α:8 μg/ml
Efficiency:94.3%
[51]
PPCN;
SDF-1α:0.5 μg /ml
Efficiency:102.8%
[49]
Immobilization through
specific heparin-mediated
interaction
Anti-thrombogenicity; efficient
adsorption; prevent enzymolysis;
sustained release; complex
operation
19%PLLA 5%PCL (w/v);
SDF-1α:0.5 μg /ml
[47]
StarPEG-heparin hydrogel;
SDF-1α:2.5 ~ 15 μg/ml;
Efficiency:99.6%
[57]
Co-Cr plates;
SDF-1α:0.25 ~ 2 μg/ml
[61]
Particulate systems Sustained release; long release
duration; multiple proteins load;
complex operation
Dex-GMA/gelatin
microcapsules (PNIPAAm
thermo gates);
SDF-1α:0.1 μg /ml
Efficiency:97.5%
[20]
PLGA nanoparticles [27]
Abbreviations: SM scaffold materials, LC loading concentration, LE loading efficiency
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material tends to absorb anions [47]. This theoretic-
ally allows electrostatic interactions to adjust between
a charged bioactive factors and an oppositely charged
molecule by changing the pH of the medium. In par-
ticular, SDF-1α has a net charge of +8 at pH 7.4 (IEP
of SDF-1α: 9.9) [50], so it is more efficient to load
into a negatively charged scaffold. In short, the re-
lease kinetics and loading efficiency of coupled bio-
active factors can easily be modulated by modifying
the ionic strength, charge density, pH and the inter-
acting scaffold.
Lee et al. [51] used a strong polycation to neutralize
excess negative charges on heparin molecules to drive
spontaneous coacervation. Since coacervation is a phase
separation process, the coating method is less dependent
on the surface properties of the scaffold [52, 53]. Thus,
SDF-1α coacervate can easily be incorporated and uni-
formly dispersed on the surface of poly(glycerol seba-
cate) (PGS) scaffolds in aqueous solution without any
exogenous chemicals. Furthermore, SDF-1α-loaded
coacervate did not block existing pores and created a
natural SDF-1α gradient from surface to the deeper layer
of the porous scaffold, allowing stem/progenitor cell
homing.
Immobilization of SDF-1α through polyion complexes
is free of linker molecules, is less dependent on the sur-
face properties of scaffold, and allows easy adjustment of
release rate. However, the process requires polarity
matched bioactive factors and polymer materials which
may limit its application.
Immobilization through specific heparin-mediated
interaction
Heparin is a highly sulfated polysaccharide which is
commonly used as an anticoagulant. Through specific
heparin-mediated interactions with chemokines [54],
chemokines can be protected from premature degrad-
ation, playing a crucial role in maintenance of physio-
logical chemokine function. In particular, SDF-1α binds
to heparin sulfate through a typical consensus sequence
for heparin recognition. Lys-1, Lys-24, Lys-27 and Arg-
41 on the surface of SDF-1α are essential for its inter-
action with heparin [54–56].
Commonly, heparin is crosslinked with the compo-
nents of the hydrogel, and SDF-1α in aqueous solutions
interacts with the modified hydrogel through a specific
heparin-mediated interaction [16, 57–60]. Alternatively,
heparin can also be covalently linked to polymer scaf-
folds through linker molecules. SDF-1α is then immobi-
lized to the conjugated heparin through its heparin-
binding domain [61]. For example, Yu et al. [47]
employed NH2-PEG-NH2 as a linker molecule attached
to the carboxylic acid groups of microfibers, and then
covalently attached heparin to the free amines of the
NH2-PEG-NH2 molecules using carbodiimide chemistry
[62]. Finally, SDF-1α was bound to heparin via the spe-
cific interaction between them. This approach ensures
that the scaffold can recruit target cells in addition to
the anti-coagulation property [54]. This study demon-
strated that SDF-1α immobilization on the scaffolds was
stable with a sustained release of SDF-1α over one week
in vitro. In addtion, SDF-1α loading efficiency is three
times higher than the direct adsorbing process [47].
In order to mimic native extracellular matrices that
provide mechanical support and chemical signals,
Tsurkan et al. [63] introduced a class of biodegradable
hydrogel that tunes its mechanical properties by the
modulation of the degree of crosslinking and degrad-
ation by a specific enzyme. Specifically, all four arms of
a hydroxyl-terminated star-polyethylene glycol (sPEG)
were modified with acrylate groups (forming sPEG-Acl).
These acrylate groups were then coupled with an MMP-
cleavable peptide sequence. In the last procedure, the N-
terminal amino groups of the sPEG-peptide were linked
to carboxylic groups of heparin molecules to create a
three dimensional network. Bioactive factors, such as
SDF-1α, could be loaded to the network through the
specific heparin-mediated interaction. Furthermore, the
degradation rate of the hydrogel could be further modu-
lated by using peptides with different enzymatic sensitiv-
ity, hence expanding the application area of the SDF-1α-
heparin containing scaffold.
Compared with direct loading or adsorption, loading
efficiency of SDF-1α is improved dramatically due to
electrostatic interactions between the positively charged
region of SDF-1α and negatively charged sulfate groups
of heparin [54, 56]. Besides, the sustained release prop-
erty of the loaded protein is also improved due to the
improved bonding strength. Furthermore, the influence
of the loading capacity on release profile should not be
ignored. Generally speaking, the more protein contained
within the scaffold the stronger the burst release will be.
Some researchers have noted that the concentration of
SDF-1α around heparin-mediated scaffolds influences
cell migration [15, 16, 64]. Thus, it is necessary to ensure
that the dose of loaded SDF-1α matches the regener-
ation process of the injured tissue.
In short, immobilization of SDF-1α through specific
heparin-mediated interactions is widely used in scaffolds
for in situ tissue engineering due to its strong inter-
action, efficient adsorption and reduced degradation.
Nevertheless, the bonding process is relatively
complicated.
Particulate systems
Micro/nano particles carriers are widely employed in
fabricating controlled drug delivery systems. The direct
loading or adsorption of a chemokine into a particulate
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system is relatively convenient to achieve. However, it is
associated with various issues such as high burst release,
protein aggregation and denaturation. In order to pre-
vent the burst release, some investigators employed
microemulsion spheres to load the chemokine. In particu-
lar, Cross and colleagues [65] incorporated SDF-1α with
poly(lactide-co-glycolide) (PLGA) microspheres using a
double emulsion solvent extraction/evaporation technique
to achieve sustained release of SDF-1α over 50 days. Add-
itionally, Wu et al. [66] applied carboxyl-polyethylene
glycol-4000-carboxyl (COOH-PEG4000-COOH) to the
surface of their microemulsion spheres. This allowed
SDF-1α to bind the microparticle through amide bonds,
enhancing loading efficiency. The loaded chemokine could
be released from the micro emulsion bubble by directed
ultrasonic waves. However, utilizing emulsification tech-
niques to fabricate protein-encapsulated particles may re-
sult in protein denaturation and the loss of bioactivity,
due to exposure of protein to organic-aqueous interfaces
[26]. Zamani et al. [27] introduced coaxial electrospraying
to prevent protein denaturation during the fabrication
process by reducing the contact time of the bioactive fac-
tors with other reactants.
In addition, micro- or nanoparticle-incorporated
hydrogels have also been widely investigated to control
the delivery of chemokines for tissue engineering appli-
cations, such as bone or cartilage regeneration [37, 67,
68]. Both temporally and spatially controlled release of
these bioactive molecules in specific sites have been
proved, thus being valuable in modulating the behavior
of encapsulated cells. Nevertheless, the loss of bioactivity
in encapsulated molecules due to high temperatures, or-
ganic solvents, and/or shear stress during the fabrication
of the micro- or nanoparticles is likely unavoidable.
Recently, In order to create smart scaffolds that
control chemokine release with time-specific, site-
specific and rate programmed characteristics, some
environmental stimuli-responsive microcapsules have
been researched [69–71]. Chen et al. [20] developed a
delivery system to control the release of SDF-1α by mak-
ing microcapsules containing thermo-sensitive polymeric
gates on their outer pore surfaces. The pore surfaces of
the microcapsules was grafted by poly(N-isopropylacry-
lamide) (PNIPAAm) using plasma-graft pore-filling
polymerization. The grafted PNIPAAm were in swol-
len state at ambient temperature, causing the pores in
the outer surfaces to be blocked and thus the release
rate of SDF-1α was low. While the temperature was
above 22 °C, grafted PNIPAAm were in shrunken
state, causing the pores in the outer surfaces to be
opened, with a corresponding increase in the release
rate of loaded SDF-1α. In addition to PNIPAAm, a
copolymer called poly(polyethylene glycol citrate-co-
N-isopropylacrylamide) (PPCN) is also characterized
by its thermoresponsive behavior, antioxidant proper-
ties and morphology, and has received attention in
protein delivery [72]. Kim et al. [73] has employed a
pH sensitive copolymer named poly (urethane amino
sulfamethazine) (PUASM) to load SDF-1α. The poly-
mer forms micelles and encapsulates proteins effect-
ively via ionic interaction at physiological pH. At
environmental pH lower than 5.5, the micelle disas-
sembles due to the ionization of tertiary amines, re-
leasing the encapsulated protein.
Self-assembled monolayer deposition is often used to
fabricate heparin-coated nanoparticles that could be uti-
lized to load SDF-1α through specific heparin-mediated
interactions. Specifically, a polyelectrolyte layer can be de-
posited onto an oppositely charged substrate through elec-
trostatic adsorption. Na et al. [74] developed a heparin/
poly(L-lysine) self-assembled nanoparticle-immobilized
PLGA microsphere system, and showed that the specific
binding activity of heparin allowed the loading of different
bioactive factors. Wang [18] discovered that load capabil-
ity and release kinetics of bioactive factors immobilized on
self-assembled particles can be modified simply by chan-
ging the ratio of heparin to polymer.
At present, some investigators have proposed the use of
particulate systems to load multiple bioactive factors by
physical absorption to facilitate tissue repair in the body
[75]. Richardson et al. [76] investigated a tissue-specific
delivery system to deliver two or more bioactive factors.
The first approach involved simply mixing lyophilized vas-
cular endothelial growth factor (VEGF) with polymer par-
ticles before processing the polymer into a porous
scaffold. The second approach involved pre-loading the
bioactive factor in PLGA microspheres, and then fabricat-
ing scaffolds with these particles. These approaches pro-
vided distinct release kinetics for each bioactive factor. A
composite scaffold comprising drug-loaded fiber and bio-
active factor-loaded microspheres was prepared by simul-
taneous electrospinning and electrospraying in our recent
work. The in vitro release test showed that the release
properties of the drug and the bioactive factor were dis-
tinct (unpublished observation). In fact, the multiple bio-
active factors-loaded particle system(including SDF-1α)
has been investigated by many researchers (Table 2). How-
ever, the optimization of the synergistic factors to promote
the tissue regeneration process remains to be done.
In summary, particulate systems are able to control
the release kinetics of bioactive factors. Furthermore, the
system allows multiple factors to be loaded into scaffolds
efficiently.
Applications
Vascular scaffolds
Replacement of diseased arteries is a common treatment.
More than 500,000 vascular grafts are used for coronary
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artery or peripheral arterial replacement each year [47].
However, autologous arterial and venous graft material
has already been deployed, or is simply unusable may
not be available in many cases [77]. Frequent occlusion
and thrombosis in smaller grafts (<6 mm) limits the
application of synthetic vascular grafts. Furthermore, the
long-term patency rate of the synthetic vascular grafts is
rather low due to the lack of endothelialization [47].
Tissue engineered vascular grafts are typically cell-based
constructs. However, harvesting vascular cells, in vitro
cell culture and making the grafts may take months.
Therefore, in situ regeneration approach that recruits
host cells is attractive.
SDF-1α is a promising chemoattractant of host EPCs
and MSCs because it induces host progenitor cell
mobilization and recruitment by binding to receptors
CXCR4 and CXCR7. However, direct injection of SDF-
1α is problematic. The short circulation half-life and
extraneous interactions with multiple binding sites all
reduce its local concentration.
Thus, it is vital to control the release of SDF-1α from
vascular grafts by using an appropriate bonding method.
Heparin could prevent thrombus formation [16, 47, 55],
and also serve as an adapter for SDF-1α binding. For in-
stance, Yu et al. [47] used NH2-PEG-NH2 to link heparin
with polymer scaffolds, and then immobilized SDF-1α.
Compared with physically-adsorbed SDF-1α, heparin-
bond SDF-1α was more stable and demonstrated sus-
tained release of SDF-1α. Furthermore, the in vivo test
revealed that the inner surfaces of the graft were covered
by endothelial cells that had differentiated from EPCs.
Six months post implantation, many microvessels were
found in the outer part of the scaffolds indicating that
heparin + SDF-1α treated grafts had been well
vascularized.
Lee et al. [51] used heparin and a polycation to
form a coacervate that was incorporated into PGS
scaffolds. This strategy also provided long-term sus-
tained release of SDF-1α in open porous structured
vascular scaffolds, which favored vascular regener-
ation. Finally, SDF-1α-containing nanoparticles have
also been used for vascular grafts because of their
sustained release characteristics [76, 78].
SDF-1α-loaded vascular grafts have many advantages,
such as cell-free and available off-the-shelf. However,
modulation of the release property of SDF-1α on grafts
to match the rate of regeneration in vivo is still
challenging.
Articular cartilage scaffolds
Articular cartilage defects can be classified as partial-
thickness, full-thickness and osteochondral defects.
Partial-thickness defects are the defects in the surface of
articular without penetratingthe tidemark, while osteo-
chondral defects are those that penetrate through the
tidemark and subchondral bone until the bone marrow.
Full-thickness defects are between the tidemark and
bone marrow. Researchers found that osteochondral and
full-thickness defects can heal spontaneously [79, 80]
while partial-thickness defects cannot [81–83], which is
attributed to the migration of stromal cells from bone
marrow. Thus, It can be inferred that recruiting stem
cells especially bone marrow stem cells (BMSCs) after
articular cartilage damages is important to rebuild the
defects.
Wei et al. [84] believe that bone marrow secreted
SDF-1α around the subchondral bone is the key point to
affect the self-repair ability compared with full-
thickness, osteochondral defects and partial-thickness
defects. Zhang et al. [85] presented an effective strategy
Table 2 Synergistic effect between SDF-1α and other bioactive factors
Bonding strategy Factors Implant position Scaffold References
Direct loading or adsorption
(Adsorb solution through inject)
SDF-1α and BMP-2 Mouse, calvarial defects Commercial collagena [94]
Gelatin hydrogels [95]
Direct loading or adsorption
(Direct loading during
manufacture process)
Mouse, ulna critical-sized
defect
Degradable hydrogels [96]
Mouse, calvarial defects/
subcutaneous sites
Commercial collagenb [97]
SDF-1α and VEGF Mouse, calvarial defects/
subcutaneous sites
Commercial collagenb [97]
SDF-1α and platelet-derived
growth factor (PDGF)
Mouse, calvarial defects/
subcutaneous sites
Commercial collagenb [97]
SDF-1α and simvastatin Mouse, calvarial defects PLGA [117]
SDF-1α and insulin-like growth
factor-1 (IGF-1)
Rat, lateral gastrocnemius
muscle of the TK-injured
limb
PEGylated fibrin gel matrix [98]
aResorbable atelocollagen sponges (Teruplug; Terudermis Olympus Terumo Biomaterials Co.)
bCollagen scaffold (Geistlich Pharma AG)
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to create an in situ matrix environment by implanting
an SDF-1α-containing type one collagen (Col1) scaf-
fold. Col1 or Col1 + SDF-1α scaffold were employed
to coverpartial-thickness defects created on the patel-
lar groove of rabbits. Meanwhile, untreated defects
were regarded as control group. The Col1+ SDF-1α
group had a significantly higher histological macro-
scopic score for moderate neo-tissue coverage, surface
regularity, and a smoother connection with the host
cartilage. This revealed that the matrix environment
created by SDF-1α loaded Col1 scaffold did improve
the spontaneous regeneration capacity of partial-
thickness defects.
Compared with the self-healing process of articular
cartilage, the regenerated tissue treated by SDF-1α scaf-
fold has mechanical properties that are more similar to
the original. Sukegawa et al. [86] used SDF-1α-loaded
alginate gel to repair osteochondral defects. A full-
thickness osteochondral defect was created in the patella
groove of the distal femur in rabbits. The compressive
modulus of regenerated tissues and the histological
scores demonstrated prominent improvement compared
with the blank control group.
One of the current limitations of bone and cartilage
tissue engineering is the lack of sufficient blood supply
in the initial phase following implantation [87]. Mean-
while, vascularization of the implant proceeds slowly
and only a few blood vessels reach the center of the scaf-
fold after several weeks [88]. Inadequate vascularization
following implantation results in nutrient deficiency,
which then leads to cell death in the tissue-engineered
scaffolds [89, 90]. In order to efficiently enhance migra-
tion of vascular cells into the scaffold, Chen et al. [91]
fabricated a collagen scaffold with radially oriented
channels and investigated its cell recruit property in
combination with SDF-1α. They found that cells infil-
trated further into the center of the scaffold. Besides,
Brouwer and his colleagues also designed a scaffold with
radial pore structure to repair the diaphragm defects,
and reached the same conclusion [92, 93]. The in vivo
experiments on rabbits confirmed that BMSCs could
also be recruited into the radially-oriented scaffold with
the assistance of SDF-1α.
Although SDF-1α loaded articular cartilage scaffolds
have been widely researched, the regenerated tissue is
still different from natural articular cartilage both in
structural constitution and mechanical properties.
Further study is necessary to optimize the structure and
component of the scaffolds, as well as loading capacity
and release property of SDF-1α.
Osseous scaffolds
Currently, SDF-1α-loaded scaffolds have been widely
used to repair bone defects (Table 2), and there is an
increasing amount of work addressing the synergy of
SDF-1α with other bioactive factors for bone repair
[15, 94–98].
Ratanavaraporn et al. [28] evaluated the activity of gel-
atin hydrogels combined with SDF-1α and bone mor-
phogenetic protein 2(BMP-2) on bone regeneration at
an ulna critical-sized defect of rats. The result demon-
strated that a SDF-1α and BMP-2-loaded scaffold was
more effective to induce bone regeneration than a scaf-
fold loaded with either factor alone. Other researchers
also found the same effect and provided some possible
explantion. On the one hand, synergetic effect of SDF-
1α and BMP-2 may influence the SDF-1α/CXCR4 or
other signal pathways to enhance cell recruitment
around scaffold. On the other hand, the enhanced re-
cruitment of HSCs improves the vascularization, which
helps to supply nutrient [99–101]. Furthermore, the
SDF-1α and BMP-2 signaling may activate osteogenic
differentiation, which improve the bone regeneration
[102, 103].
It is well known that several members of the BMP
family, including BMP-2, −4,−6, −7, and −9, can in-
duce MSCs to undergo osteogenic differentiation and
promote bone formation [104–107]. However, using
BMPs has some disadvantages, including ease of deg-
radation and high cost [108–110]. Simvastatin (SIM)
is a competitive inhibitor of 3-hydroxy-3-methyl coen-
zyme A (HMGCoA) reductase, which improves the
osteogenesis of adipose-derived stromal cells (ASCs)
[111]. Meanwhile there have been many studies dem-
onstrating the promotion of bone regeneration by the
local application of SIM with different delivery sys-
tems in various animal models [112–115]. Further-
more, SIM has recently been shown to mobilize
MSCs migrating to bone defects or areas of spinal
cord injury [116]. Thus, Liu et al. [117] fabricated a
PLGA-based cell-free bone tissue engineering scaffold
loaded with SIM and SDF-1α, and applied it in
critical-sized calvarial defects in mice. Their findings
suggest that the combination of SDF-1α and SIM in-
creases MSCs migration and homing, promotes angio-
genesis and enhance the expression of BMP-2 in
newly-formed bone tissue.
Richardson et al. [76] investigated a polymeric system
that allowed for the tissue-specific delivery of two or
more bioactive factors with controlled dose and release
rate. Briefly, a porous PLGA scaffold loaded with mul-
tiple growth factors was fabricated by a high-pressure
carbon dioxide fabrication process. Two types of strategy
were used to load bioactive factors, processing the poly-
mer into a porous scaffold. One bioactive factor was
simply mixed with polymer particles which lead to rapid
release. Another bioactive factor was pre-encapsulated
in PLGA microspheres which lead to a comparatively
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slower release rate. The scaffold was fabricated with
these particles.
The therapeutic effect of multiple bioactive factors
contained within the scaffold system was more dra-
matic than the single factor system. Nevertheless,
there are still many problems which limit its develop-
ment. For instance, the preparation process of the
scaffold with its multiple bioactive factors is compli-
cated, and its molecular mechanism and the safety of
the system remain to be investigated. In order to
mimic the process of natural bone healing, the ideal
smart multiple bioactive factors loaded scaffold sys-
tem should control the release sequence as well as
the release rate of each factor.
Myocardium scaffold and other applications
The deterioration of cardiac function following myocar-
dial infarction (MI) is a major cause for high mortality
due to heart disease [118]. It is important to ensure
myocardium regenerates after MI. As for cell therapy,
poor cell engraftment in the myocardium limits the effi-
ciency of using stem/progenitor cells to treat MI [31].
Investigators have demonstrated that myocardial SDF-
1α expression is temporarily increased following MI
[119, 120]; however, long-term SDF-1α release is
necessary for cardiac regeneration.
As for SDF-1α-loaded MI scaffolds, achieving sus-
tained release and preventing premature enzymatic deg-
radation of the loaded chemokine are critical. Zhang et
al. [32] introduced a PEGylated fibrin patch to deliver a
sustained flux of SDF-1α to an acute MI (AMI) site. Spe-
cifically, PEGylated fibrin patch was fabricated by mixing
thrombin with SDF-1α incorporated PEGylated fibrino-
gen. An in vitro study demonstrated that SDF-1α was
successfully released from the patch over 10 days. The in
vivo release study in mouse MI model indicated that the
controlled release of SDF-1α from a PEGylated fibrin
patch significantly recruited more c-kit + cells to the in-
farct area at the second week than did the direct injec-
tion group. This phenomenon was observed for up to
4 weeks following implantation. It revealed that SDF-1α
contained within a PEGylated fibrin patch could over-
come premature degradation and it healed AMI through
sustained chemokine release. Some researchers have
adopted SDF-1α-linked hydrogel to achieve a long re-
lease duration and high loading efficiency for MI treat-
ment [16, 31, 121].
Despite recent research showing SDF-1α-loaded MI
scaffolds could help to repair heart injury following MI,
it remains a challenge to determine the best release
property, especially the concentration of the chemokine
around the scaffold for safe and efficient treatment.
This review only covers applications in several tissues.
There are also studies on other tissue injures such as
skin ulcers [49, 122], traumatic brain injury [123], and
intervertebral disc degeneration [33] because of the abil-
ity of SDF-1α-loaded scaffolds to recruit cells.
Conclusions
SDF-1α-loaded scaffolds have been adopted to investi-
gate the regeneration of blood vessels, myocardium,
cartilage, bone and many other tissues. Most investi-
gators adopt physical immobilization to load SDF-1α,
especially direct loading or adsorption due to its ease
of operation. Furthermore, immobilization of cues
through the formation of ionic complexes is appropri-
ate for the loading of SDF-1α for its universality, rela-
tive strong interaction, lack of linker molecules,
reduced dependence on surface properties, and the
protection of immobilized factors from inactivation.
However, the disadvantages of physical immobilization
are also clear. Uncontrolled burst release and short
release duration limit its application. In order to re-
strain the burst release and prolong the release dur-
ation of SDF-1α from scaffolds, some researchers
have introduced heparin-mediated immobilization. For
example, an amidation reaction between heparin and
scaffold has been utilized. SDF-1α is then incorpo-
rated into the scaffold through the specific heparin-
mediated interaction. Furthermore, micro-carrier
immobilization can also provide sustained release of
SDF-1α by loading bioactive factors into nano- or
micro-polymer particles. The SDF-1α-loaded particle
is mixed with raw materials to fabricate the scaffolds
or simply coated on the surface of scaffolds. The
most remarkable merit of the particulate system is
that it provides microcarriers to load multiple bio-
active factors that may promote effective cell migra-
tion, growth and differentiation. These bonding
strategies may also be expanded to immobilize other
chemokines or growth factors. For in vivo applica-
tions, it is critical to prevent the enzymatic degrad-
ation of SDF-1α upon release from the scaffolds.
Therefore, protease-resistant SDF-1α may have poten-
tial applications for in situ tissue regeneration.
It has been found that the release kinetics, loading effi-
ciency and cell homing capability of SDF-1α-loaded scaf-
folds depend on their bonding strategies. To mimic a
physiological cellular microenvironment, one needs to
consider the nature of the bonding strategy the scaffold
should adopt for its application. It is likely that a SDF-
1α-loaded scaffold may be loaded with multiple bioactive
factors through a combined use of different bonding
strategies, in which synergistic effects of the bioactive
factors can arise. Specifically, it may become a future
trend to control the release sequence as well as the re-
lease rates of the multiple bioactive factors by choosing
appropriate bonding strategies for each bioactive factor.
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